The global protein a resins industry size is projected to reach US$ 677.84 million in 2023. According to a recent analysis by Future Market Insights, the market would likely reach US$ 1,477.01 million by 2033. From 2023 to 2033, the market is projected to grow at a CAGR of 8.1%.
Protein A resins are used in the creation of monoclonal antibodies at a remarkable rate. Demand for monoclonal antibodies has skyrocketed in therapeutic fields like cancer, autoimmune, neurological, and inflammatory illnesses. Naturally, the development and research of therapeutic antibodies is where the attention of top pharmaceutical corporations is focused. This will advance the medical industry as a whole. The investigation of monoclonal antibodies, the expedited speed of drug development assumed by the biopharmaceutical and biotechnology industries, and increased investment in synthetic biology are some prevalent reasons driving the industry ahead.
Request A Sample Copy of This Research Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-1720
The rising demand for protein-engineered products utilized for therapeutics and vaccine development by the biopharma industries is expected to fuel market growth. Additionally, elevated demand for pre-packed disposable columns positively impacts the market. Government fundings for new research are likely to be high in developed countries such as the United States. This is additionally underpinned by superior quality infrastructure held by the country. Furthermore, the pharmaceutical industry is making substantial efforts to advance the medical field and bridge the gap between patients and healthcare facilities by working on therapeutics’ cost-effectiveness.
Progress in Demand for monoclonal antibodies research is expected to uplift the market. It is also expected to unveil noteworthy growth prospects for players showing interest in this market. Manufacturers are also considering shifting their base to emerging territories like China and Japan, which show notable demand for protein A resins.
Top Highlights from the FMI’s Analysis of the Protein A Resins Market:
Newsflash Straight from Leading Market Players:
Navigo Proteins GmbH introduced an affinity resin extracted from a baculovirus insect cell known as glycoprotein gp64 in June 2022. For the success of this process, precision capture technology was deployed. This resin can be employed for the vaccine production process.Agilent Technologies joined forces with Delaware State University in September 2022 to accelerate the base of minority students who opt for STEM careers.Tosoh Biosciences LLC finalized its acquisition of Semba Biosciences in October 2021. The latter is a privately held prominent innovator in multi-column chromatography (MCC) technology and instrumentation. With this recent development, the former company is expected to observe ease in the downstream purification of biologics.Navigo and Repligen fulfilled their co-development of a new affinity ligand in September 2021.The Life Sciences operations of GE Healthcare were obtained by Danaher Corporation and remarketed as Cytiva in May 2021.Key Players in the Market are:
GE HealthcareThermo Fisher ScientificKaneka Corporation,JNC CorporationPurolite Life SciencesBio-Rad Laboratories, Inc.JSR Corporation (JSR Life Sciences LLC)RepligenTosoh Bioscience, Merck Group (Merck Millipore)Novasep Holdings SAS, Agilent Technologies, Inc.GenScript, Abcam PLC (Expedeon Ltd.)Avantor Inc.Takara Bio, PerkinElmer, Inc.Suzhou Nanomicro Technology Co., LtdProtein A Resins Market by Category:
Product:
Natural Protein A ResinRecombinant Protein A ResinMatrix:
Agarose-based MatrixGlass or Silica-based MatrixOrganic Polymer-based MatrixApplication:
ImmunoprecipitationAntibody PurificationEnd User:
Biopharmaceutical ManufacturersClinical Research LaboratoriesAcademic InstitutesRegion:
North AmericaLatin AmericaEuropeEast AsiaSouth AsiaOceaniaThe Middle East and Africa (MEA)
Sign in to leave a comment.